XML 19 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes In Stockholders' Equity - USD ($)
Series A
Preferred Stock
Common Shares
Common Stock
Share Subscription Receivable
Additional Paid-in- Capital
Reserves
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Total Mawson Stockholders’ Equity
Non- controlling interest
Total
Balance at Dec. 31, 2019     $ (459,062) $ 28,902,874   $ (345,182) $ (21,125,291) $ 6,973,339   $ 6,973,339
Balance (in Shares) at Dec. 31, 2019 6,578,672                  
Issuance of stock options                    
Issuance of common shares, exercise of warrants       5,554,177 $ 652,949     6,207,126   6,207,126
Issuance of common shares, exercise of warrants (in Shares)   960,603                  
Net loss             (5,034,248) (5,034,248) $ (27,066) (5,061,314)
Other comprehensive loss         (996,644)   (996,644)   (996,644)
Receipt of share subscriptions proceeds     442,372             442,372
Balance at Dec. 31, 2020 $ 7,539,275 (16,690) 34,457,051 652,949 (1,341,826) (26,159,539) 7,591,945 (27,066) 7,564,879
Balance (in Shares) at Dec. 31, 2020 7,539,275                  
Exchange of stock and Reverse recapitalization of Wize Pharma Inc $ (7,539,275) $ 511,882 (5,436,541) (4,924,659) (4,924,659)
Exchange of stock and Reverse recapitalization of Wize Pharma Inc (in Shares) 178   51,188,168                
Issuance of common stock, net of offer costs, PIPE transaction $ 25,000 2,975,000 3,000,000 3,000,000
Issuance of common stock, net of offer costs, PIPE transaction (in Shares)     2,500,000                
Issuance of convertible notes, net of offer costs 20,301,427 20,301,427 20,301,427
Issuance of warrants (7,571,740) 16,817,286 9,245,546 9,245,546
Issuance of common stock, net of offering costs / at-the market offerings $ 8,592 74,912,708 74,921,300 74,921,300
Issuance of common stock, net of offering costs / at-the market offerings (in Shares)     8,622,561                
Fair value of IPR&D acquired, net of Business Combination transaction costs 24,765,831 24,765,831 24,765,831
Fair value adjustment of LO2A intellectual property revenue sharing obligation 5,440,863 5,440,863 5,440,863
Issuance of common stock, stock based compensation $ 4,140 358,104 5,782,051 6,144,295 6,144,295
Issuance of common stock, stock based compensation (in Shares)     198,921                
Issuance of common stock, settlement of convertible note interest $ 8,691 851,680 860,371 860,371
Issuance of common stock, settlement of convertible note interest (in Shares)     86,959                
Issuance of RSU’s and stock options 890,251 10,332,552 11,222,803 11,222,803
Issuance of common stock, conversion of Series A preferred stock  
Issuance of common stock, conversion of Series A preferred stock (in Shares) (178)   17,800                
Issuance of common stock, on conversion of convertible notes $ 63,627   63,627 63,627
Issuance of common stock, on conversion of convertible notes (in Shares)     6,362,690                
Issuance of common stock, exercise of warrants $ 1,820 13,468,875 (13,346,668) 124,027 124,027
Issuance of common stock, exercise of warrants (in Shares)     1,744,848                
Issuance of stock by subsidiary to non-controlling interest 406,534 406,534 511,150 917,684
Purchase remaining non-controlling interest of Luna Squares LLC (241,713) (241,713) (150,766) (392,479)
Exercise of RSU’s $ 24 60,913 (60,937)
Exercise of RSU’s (in Shares)     24,375                
Other $ (12,272) 16,690 (38,412)   (33,994) (33,994)
Other (in Shares)     186                
Net loss (44,963,720) (44,963,720) (44,963,720)
Other comprehensive loss 820,732 820,732 820,732
Non-controlling interest (497,944) (497,944)
Balance at Dec. 31, 2021 $ 611,504 $ 165,600,831 $ 20,177,233 $ (521,094) $ (71,123,259) $ 114,745,215 $ (164,626) $ 114,580,589
Balance (in Shares) at Dec. 31, 2021   70,746,508